<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To evaluate the maternal and fetal outcome in a cohort of women undergoing a subsequent pregnancy after a previous cerebrovascular event in the presence of <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS: Fifteen pregnancies were followed up in 12 women with past cerebrovascular events and thrombophilic disorders </plain></SENT>
<SENT sid="2" pm="."><plain>The cerebrovascular events occurred during a previous pregnancy in five patients </plain></SENT>
<SENT sid="3" pm="."><plain>Six patients had a bad obstetric history including intrauterine fetal <z:hpo ids='HP_0011420'>death</z:hpo> in four cases, early <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0341950,C0156669" disease_type="Disease or Syndrome" abbrv="">severe preeclampsia</z:e> in two cases and one infant that was <z:hpo ids='HP_0001518'>small for gestational age</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>THE THROMBOPHILIC DISORDERS INCLUDED: anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> syndrome, protein C, S or <z:hpo ids='HP_0001976'>antithrombin III deficiencies</z:hpo>, mutations of the <z:chebi fb="0" ids="25345">methyltetrahydrofolate</z:chebi> reductase (MTHFR) </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received prophylactic treatment with low molecular weight <z:chebi fb="5" ids="28304">heparin</z:chebi> and low dose aspirin </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Thromboembolic complications occurred in four pregnancies </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="C0852263" disease_type="Disease or Syndrome" abbrv="">Postpartum complications</z:e> occurred in one patient; <z:hpo ids='HP_0002625'>deep vein thrombosis</z:hpo> and <z:e sem="disease" ids="C0034065" disease_type="Disease or Syndrome" abbrv="">pulmonary emboli</z:e> after stopping anticoagulation treatment </plain></SENT>
<SENT sid="8" pm="."><plain>No patient had long-term neurologic damage </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> pregnancies except one resulted in live births </plain></SENT>
<SENT sid="10" pm="."><plain>(mean gestational age at delivery 36 +/- 3 </plain></SENT>
<SENT sid="11" pm="."><plain>7 weeks, mean birth weight 2656 +/- 811 g) </plain></SENT>
<SENT sid="12" pm="."><plain>The one remaining pregnancy was electively terminated </plain></SENT>
<SENT sid="13" pm="."><plain>There was one <z:hpo ids='HP_0003811'>neonatal death</z:hpo> due to the complications of severe <z:e sem="disease" ids="C0728731" disease_type="Disease or Syndrome" abbrv="">prematurity</z:e> in a woman with severe <z:e sem="disease" ids="C0162739" disease_type="Disease or Syndrome" abbrv="HELLP">HELLP syndrome</z:e> </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSION: This preliminary data suggests that women with a history of cerebrovascular events and thrombophilic disorders receiving prophylactic treatment, have a relatively favorable pregnancy outcome; however, they remain at significant risk during pregnancy </plain></SENT>
<SENT sid="15" pm="."><plain>Further studies are necessary to determine the optimal prophylactic treatment </plain></SENT>
</text></document>